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Abstract. The effects of intravenous acetylsalicylic acid (1.0 g
bolus) on renal function and prostaglandin synthesis were
evaluated in a prospective, controlled study in eight patients
in an intensive care unit. Four of these patients had con-
gestive heart failure. Administration of acetylsalicylic acid
caused significant antidiuresis (-56%), antinatriuresis
(-82%), renin suppression (-26%) and decreased GFR
(-41%). All of these changes were completely reversible
within 1-2 hours and tended to be more pronounced in the
patients with congestive heart failure. Urinary excretion of
prostaglandin E2 was depressed profoundly (-93%) and
did not return to more than 45% of control 6 h after the
administration of acetylsalicylic acid.
We conclude that intravenous acetylsalicylic acid affects
kidney function in a manner similar to other prostaglandin
synthesis inhibitors. Its effects are, however, short-lived.
The inhibition of urinary PGE2 excretion outlasts GFR
depression, antidiuresis, antinatriuresis and renin
suppression by several hours.
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Introduction
It is well recognized that prostaglandin synthesis inhibitors
(PGSI) may impair renal function, particularly when
effective arterial blood volume (EABV) is reduced. Thus,
deterioration of renal function induced by PGSI has been
described in sodium depletion [1], liver cirrhosis [2,3],
nephrotic syndrome [4] and congestive heart failure
(CHF) [5]. It has been proposed that renal blood flow
becomes dependent on vasodilatory prostaglandins pro-
duced in the kidney whenever effective arterial blood
volume is reduced [6]. These vasodilatory prostaglandins
are thought to counteract increased catecholamine- and
angiotensin-mediated vasoconstriction. Substances which
reversibly inhibit cyclo-oxygenase, but have a relatively long
pharmacological half-life, such as indomethacin, have been
used in most studies. A similar effect, however, has not
conclusively been shown for acetylsalicylic acid (ASA),
which irreversibly inactivates cyclo-oxygenase [7,8], but
has a half-life of only 10-15 minutes [9]. Additionally,
aspirin in an injectable form (lysine-ASA, Aspegic) has
been frequently used as an analgesic and antipyretic drug in
our intensive care unit (ICU). We therefore undertook a
study to assess the effects of intravenous aspirin on kidney
function in ICU patients with and without congestive heart
failure.
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Methods
Patients
All patients admitted to the medical ICU of the
Kantonsspital Basel between 1 September 1982 and 31
December 1982 were evaluated for the following entry cri-
teria: (1) age above 40 years, (2) creatinine clearance above
20 ml/min, (3) the presence of an urinary catheter that would
probably not be removed for the next 2 days, (4) no use of
PGSI in the past 24 h, (5) no bleeding tendency and (6) no
history of salicylate allergy. Only patients who fulfilled all
these criteria were entered. Eight patients qualified for entry,
all of whom completed the study (six men and two women;
mean age 68; range 50-85 years). Admitting diagnoses
included hypoxic brain damage after cardiac arrest due to
myocardial infarction (three patients), congestive heart fail-
ure due either to chronic coronary heart disease (two
patients) or to recent myocardial infarction (one patient),
Pickwickian syndrome (one patient) and Guillain-Barre
syndrome with tetraplegia (one patient). Presence or absence
of congestive heart failure was determined prospectively in
all eight patients. CHF was diagnosed, if two or more of the
following criteria were present: (1) pulmonary capillary
wedge pressure (PCWP) or pulmonary artery diastolic
pressure (PAd) above 15 mmHg (measured without PEEP),
(2) jugular vein distension or central venous pressure (CVP)
above 12 mmHg, (3) pulmonary venous congestion on chest-
x-ray, (4) basal pulmonary rales. There were four patients
with and four without CHF.
Informed oral consent was obtained either from the
patients, or from relatives if the patient was unable to com-
municate. The study was approved by the Ethical Committee
of the University Hospital of Basel.
Protocol
Studies were performed on two consecutive days for every
patient. Aspirin 1.0 g was given intravenously on one day
while on the other day only a blood sample was drawn at the
corresponding time. The sequence for each patient ('aspirin
day'—'control day' or vice versa) was established separately
within the 'non-CHF' and 'CHF' groups using a random
sequence.
Before measurements, a thin plastic tube (Bard-I-Cath,
normally used for peripheral vein cannulation) was intro-
duced into the urinary catheter and advanced to its tip for air
washout of bladder and catheter between urinary collec-
tions. The protocol was started between 8.00 and 10.00 a.m.
with an intravenous loading dose of 0.5 ml 10% inulin
(Inutest, Laevosan-Gesellschaft, Linz, Austria) followed by
a continuous i.v. infusion of 5% glucose plus inulin. The
inulin concentration in the infusion was calculated individu-
ally to yield an infusion rate of 0.25 mg/min x estimated
16S
GFR in an infused volume of 90-100 ml/h. At least 75 min
were allowed for equilibration. Urine was then collected at
60-minute intervals for a total of 8 h. For prostaglandin
determination, urine was collected in glass containers
previously washed in methanol; samples were immediately
frozen at -17°C. Urine samples with macroscopic haema-
turia were excluded from this determination. Blood samples
were drawn at 1-h intervals for serum inulin, and at 2-h
intervals for serum creatinine determination. Aspirin 1.0 g in
a soluble preparation (lysine-ASA, Aspegic) was injected
after two control urine collection periods, and measurements
were continued for the subsequent 6 h. Plasma renin activity
(PRA), noradrenaline and adrenaline were determined
immediately before ASA, 1 h and 4 h after ASA, and at the
corresponding times on the control day. Plasma salicylate
levels were determined 1 h and 4 h after injection.
The treating physicians were not informed about the study
phase in each individual patient (ASA day or control day).
However, the investigation was not formally designed as a
double-blind study. No prostaglandin synthesis inhibitors
were allowed during the study, but with this exception the
physicians in charge were not restricted in their therapeutic
measures. Patients on diuretics or vasodilators were con-
tinued on their previous therapeutic schedule. Intravenous
fluids were administered at a constant rate. Fluid and
diuretic therapy was not changed during the 8 study hours.
Determinations
Serum and urine inulin was determined enzymatically [10].
Serum and urine electrolytes and creatinine were measured
by a Technicon auto-analyzer. PGE2 in urine was deter-
mined by radioimmunoassay (RIA) following extraction
and purification by thin-layer chromatography. This
method has previously been described and shown to yield
results in agreement with mass spectrometric determin-
ations [11]. Plasma renin activity (PRA) was determined as
described [12]. Adrenaline and noradrenaline were deter-
mined by RIA [13]. Salicylate levels were determined by the
Trinder method [14].
Statistical evaluation
Urinary prostaglandin determination was not carried out in
patient No. 2 because of macrohaematuria. Patient 6, in the
second hour after ASA, was so oliguric that prostaglandins
could not be assayed. With these exceptions, data collection
was complete.
Data were analysed separately for the ASA and control
days by 2-way analysis of variance, using time and individual
patients as influencing factors. Logarithmic transformation
was used for all parameters except the Cjnu,in/Ccreil,ininc.
ratio. All 'mean values' in this paper therefore represent
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mean values of the decimal logarithms of the original
parameters, which were transformed back to the original
scale by 10* for better comparison. Although not used in
the calculations, standard errors of the log-means are indi-
cated, to enable evaluation of the variability between
patients. A parameter was considered significantly different
from baseline if the analysis of variance yielded a significant
F-test for treatments (i)<0.05) and if, in addition, the value
was found to be significantly different from each of the two
control measurements using Duncan's new multiple range
test with P< 0.05 [15,16].
Results
Inulin clearance (Fig. 1) decreased significantly from
65 ml/min to 38 ml/min in the first hour after ASA. The
decrease in inulin clearance was also significant in the four
patients with CHF (decrease from 51 ml/min to 26 ml/min in
the second hour after ASA). The smaller decrease in the
patients without CHF (83 ml/min to 50 ml/min) was not
significant. No change was observed on the control day.
CD Control day
S3 Before ASA
After ASA
Control I 2 3
Hours after ASA
Fig. 1. Inulin clearances of the eight patients on control (white bars) and
ASA days (hatched bars). The ANOVA for the ASA day was significant for
an effect of treatment (P< 0.005). 'denotes significant difference from both
control values pre-ASA in Duncan's test (/><0.05). Data are presented as
log means and log SEMs.
Creatinine clearance paralleled inulin clearance. There was
no significant change in the Cioulin/Ccre,tinine ratio on both
ASA and control days (Table 1).
Urine volume (Table 1) decreased significantly from
104 ml/min to 46 ml/min in the second hour after ASA. As
with inulin clearance, changes tended to be more pro-
nounced in the CHF subgroup (decrease from 117 to
31 ml/min 2h after ASA, P<0.05) than in the subgroup
without CHF (decrease from 93 to 58 ml/min; not signifi-
cant). No change was seen on the control day.
Urinary sodium excretion (UNaV, Table 1) decreased sig-
nificantly from 49 uEq/min to 9 uEq/min in the second hour
after ASA. The changes in the two subgroups were not sig-
nificant, due to considerable variation both between and
within patients. No change was observed on the control day.
ASA significantly decreased urinary PGE2 excretion
(UPGE2V, Fig. 2) from 27 ng/h to a minimum of 2 ng/h
during the second hour after ASA. Even 6h after ASA,
PGE2 excretion had not returned to more than 12 ng/h.
However, in the four patients given ASA on day 1 and in
whom PGE2 determination was repeated after 24 h, PGE2
excretion had completely recovered. There was no signifi-
cant change on the control day. Baseline values showed no
clear-cut difference between CHF and non-CHF patients, in
fact the two highest rates and the lowest rate were found in
the CHF group.
PGE.
O Control day
KS Before ASA
After ASA
Control
Hours after ASA
Fig. 2. Urinary PGE2 excretion of seven patients on control (white bars) and
ASA days (hatched bars). The ANOVA for the ASA day was significant for
an effect of treatment (P< 0.001). 'denotes significant difference from both
control valyes pre-ASA in Duncan's test (/><0.05). Data are presented as
log means and log SEMs.
Plasma renin activity was higher on average in the CHF
compared to the non-CHF group. When both groups were
analysed together, there was a significant decrease at 1 h after
ASA from 23 ng Al/ml per h to 17 ng Al/ml per h (Table 1).
No significant change was observed on the control day.
Plasma adrenaline and plasma noradrenaline levels were
very high in all patients. Pre-ASA values were 231 +
1.3ng/ml for adrenaline (normal 15-80 ng/ml) and
1335+ 1.2 ng/ml for noradrenaline (normal: 140-700 ng/ml).
No significant change was found.
Serum salicylate levels decreased from a mean of
0.49nmol/l (range 0.36-0.57 nmol/1) l h after ASA to
0.36 nmol/1 (range 0.27-0.48 nmol/1) 4 h after ASA. There
was no difference between CHF and non-CHF patients.
Discussion
The most prominent effects of ASA in this study were GFR
depression, antidiuresis, antinatriuresis, and renin sup-
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Table 1. Urine volume, urinary sodium excretion, plasma renin activity and C
167
, ratio
Urine volume
(ml/h)
uN,v(ueq/min)
Plasma renin
activity
(ngAI/ml/h)
^-"inulin/
^"creatinine
Day
Control
ISEM
ASA
:SEM
Control
:SEM
ASA
!SEM
Control
ISEM
ASA
:SEM
Control
+ SEM
ASA
+ SEM
Before
71
1.3
93
1.3
43
1.9
40
1.8
0.98
0.04
1.07
0.07
ASA
65
1.3
117
1.3
31
2.0
61
1.5
17
1.8
23
1.4
1.06
0.06
1.02
0.07
Hours after ASA
1
71
1.3
54
1.1
36
1.8
23
1.5
18
1.6
17»
1.4
1.08
0.04
1.03
0.09
2
99
1.4
46*
1.4
46
1.7
9*
1.7
1.01
0.06
1.07
0.06
3
81
1.4
86
1.4
26
2.1
19
1.6
1.02
0.03
1.00
0.07
4
102
1.3
100
1.3
63
1.9
32
1.6
17
1.7
20
1.4
1.00
0.03
0.98
0.05
5
121
1.4
103
1.3
73
1.6
42
1.5
1.02
0.07
0.92
0.08
6
103
1.3
95
1.4
58
1.8
37
1.7
0.96
0.05
1.06
0.07
lvalue*
n.s.
P<0.01
n.s.
P<0.05
n.s.
P<0.05
n.s.
n.s.
All numbers are the mean values (n = 8) of the logarithms transformed back to the original scale; to obtain the +1 SEM interval,
multiply or divide the means by the SEMs. The Cinil|jn/Cere.linine values are arithmetic means ± SEM.
°P value of the F-Test for treatments (observation periods) in the 2-way ANOVA. A significant P value indicates that the
differences between observation periods exceed the random variation.
'denotes significant difference from both control values of the same day in Duncan's test.
pression, which are well-known renal effects of prostaglan-
din synthesis inhibitors. Up to now, however, no study has
reported the full spectrum of PGSI effects after ASA. For
example, renin suppression was never found [1,17], and in
one study the absent antidiuretic or antinatriuretic effects
of ASA were contrasted with the pronounced effects of
indomethacin[18].
Based on current knowledge, it is plausible that prosta-
glandin (PG) inhibition should cause the effects observed.
GFR depression is usually attributed to unopposed pre-
glomerular vasoconstriction [6]. As prostaglandins are
known to antagonize the hydro-osmotic effects of antidiure-
tic hormone (ADH) on the distal nephron [19,20], PGSI-
induced antidiuresis is explained by enhanced ADH action in
the absence of prostaglandins. Mechanisms considered for
PGSI-induced antinatriuresis include: (a) renal vasocon-
striction by lack of vasodilatory prostaglandins [21,22,23],
(b) more avid distal tubular sodium reabsorption which
would normally be inhibited by prostaglandins [23], and (c)
direct aldosterone-like effects of PGSIs, particularly ASA
[17]. Finally, renin release is stimulated by prostacyclin
(PGI2) [24,25,26], and, accordingly, renin suppression has
frequently been described after indomethacin [21,27,28,29].
It is of interest that in our study, all of these effects were
much shorter in duration (2h) than the effect on PGE2
excretion, which, 6 h after ASA, was still 50% below base-
line. PGE2 in urine originates from the kidney [30], and
reflects essentially medullary cyclo-oxygenase activity
[24,31]. As ASA acetylates cyclo-oxygenase irreversibly [7,8],
and as its metabolite salicylic acid does not inhibit prosta-
glandin synthesis in oral doses up to 1.2 g t.i.d. [32], it can be
inferred that the gradual recovery of PGE2 excretion in our
study reflects resynthesis of medullary cyclo-oxygenase.
Several explanations for this incongruence in the time
course of PGSI-effects and PG synthesis inhibition are con-
ceivable: GFR depression and renin suppression could revert
earlier, because resynthesis of cyclo-oxygenase in the renal
cortex might be more rapid than in the medulla; furthermore,
only relatively little cyclo-oxygenase activity might be
needed to counteract vasoconstriction. The rapid reversal of
antidiuresis could indicate that medullary PGE2 synthesis is
not relevant to the effects of ADH on the distal nephron,
or that overriding regulatory mechanisms came into play
to restore urine output. Similar explanations apply to
antinatriuresis.
In comparing our data with earlier studies on ASA, one
notes that GFR effects of similar magnitude were observed
only by Berg [22], who administered 750 mg of ASA intra-
venously to patients with chronic renal failure, which caused
GFR to decrease by 40%. Some of the lupus patients studied
by Kimberly and Plotz [33] under therapy with oral ASA also
experienced large reductions in GFR. Using 1.0 g of intra-
venous ASA, Robert et al. [34] studied eight patients recover-
ing from minor illness, and found an average reduction in
Qnuiin °f 30%. The remaining studies found little or no effect
on GFR [1,17,35,36]. All of them used oral ASA. We could
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not confirm the finding of Burry and Dieppe [35] that ASA
caused a decrease in creatinine clearance (not GFR) due to
inhibition of tubular creatinine secretion. The following
factors might have contributed to the magnitude of GFR
reduction in our study:
(1) Oral vs. iv. ASA. Given the low bioavailability of ASA
after oral ingestion (approximately 50% with single ASA
doses of up to 1300 mg, [9]), it is conceivable that i.v. ASA
inhibits PG synthesis much more effectively than oral ASA.
Although Vierhapper et al. [18] found similar (70-75%)
inhibition of UPGE2V with 3 g/day of oral ASA and with
indomethacin 150 mg/day, this does not rule out differences
in renal cortical PG synthesis inhibition.
(2) Reduced effective arterial blood volume (EABV).
EABV was certainly reduced in the patients with CHF, as
evidenced by their low baseline GFR. After ASA, GFR
seemed to decrease to a greater extent in these patients, but
the difference between the CHF and non-CHF groups was
not significant, and even without CHF or clinical evidence of
reduced EABV, two patients had large reductions in GFR of
48% and 71%.
(3) Vasoconstrictors. Our patients had high levels of
adrenaline, noradrenaline and renin. Noradrenaline, and
under certain conditions angiotensin II, are potent stimu-
lators of renal PG synthesis in vivo [37] and in vitro [38,39].
Although catecholamine levels did not correlate with the
magnitude of GFR depression, the two non-CHF patients
who experienced the least decrease in GFR (-3% and -9%)
also had the lowest (almost normal) plasma adrenaline and
noradrenaline levels of all the study patients.
In summary, we conclude that intravenous ASA affects
kidney function in a manner similar to other PGSIs. Its
effects are, however, short-lived. Medullary PG synthesis
inhibition outlasts GFR depression, antidiuresis, anti-
natriuresis and renin suppression by several hours.
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